Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Identifying prognostic structural features in tissue sections of colon cancer patients using point pattern analysis.

Jones-Todd CM, Caie P, Illian JB, Stevenson BC, Savage A, Harrison DJ, Bown JL.

Stat Med. 2019 Apr 15;38(8):1421-1441. doi: 10.1002/sim.8046. Epub 2018 Nov 28.

PMID:
30488481
2.

Evidences of strong sources of DFe and DMn in Ryder Bay, Western Antarctic Peninsula.

Bown J, van Haren H, Meredith MP, Venables HJ, Laan P, Brearley JA, de Baar HJW.

Philos Trans A Math Phys Eng Sci. 2018 Jun 28;376(2122). pii: 20170172. doi: 10.1098/rsta.2017.0172.

3.

Towards the elimination of paediatric tuberculosis in high-income, immigrant-receiving countries: a 25-year conventional and molecular epidemiological case study.

Dhawan V, Bown J, Lau A, Langlois-Klassen D, Kunimoto D, Bhargava R, Chui L, Collin SM, Long R.

ERJ Open Res. 2018 May 8;4(2). pii: 00131-2017. doi: 10.1183/23120541.00131-2017. eCollection 2018 Apr.

4.

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.

Kankia IH, Khalil HS, Langdon SP, Moult PR, Bown JL, Deeni YY.

Oxid Med Cell Longev. 2017;2017:1864578. doi: 10.1155/2017/1864578. Epub 2017 Dec 19.

5.

Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002.

Goltsov A, Tashkandi G, Langdon SP, Harrison DJ, Bown JL.

Eur J Pharm Sci. 2017 Jan 15;97:170-181. doi: 10.1016/j.ejps.2016.11.008. Epub 2016 Nov 8.

6.

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.

Khalil HS, Langdon SP, Goltsov A, Soininen T, Harrison DJ, Bown J, Deeni YY.

Oncotarget. 2016 Nov 15;7(46):75874-75901. doi: 10.18632/oncotarget.12425.

7.

A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT.

Bown JL, Shovman M, Robertson P, Boiko A, Goltsov A, Mullen P, Harrison DJ.

Oncotarget. 2017 May 2;8(18):29657-29667. doi: 10.18632/oncotarget.8747.

8.

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.

Khalil HS, Langdon SP, Kankia IH, Bown J, Deeni YY.

Oxid Med Cell Longev. 2016;2016:4148791. doi: 10.1155/2016/4148791. Epub 2015 Dec 7.

9.

Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells.

Khalil HS, Goltsov A, Langdon SP, Harrison DJ, Bown J, Deeni Y.

J Biotechnol. 2015 May 20;202:12-30. doi: 10.1016/j.jbiotec.2014.09.027. Epub 2014 Nov 5.

PMID:
25449014
10.

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.

Goltsov A, Deeni Y, Khalil HS, Soininen T, Kyriakidis S, Hu H, Langdon SP, Harrison DJ, Bown J.

Cells. 2014 Jun 10;3(2):563-91. doi: 10.3390/cells3020563.

11.

Evidence for the use of dry needling and physiotherapy in the management of cervicogenic or tension-type headache: a systematic review.

France S, Bown J, Nowosilskyj M, Mott M, Rand S, Walters J.

Cephalalgia. 2014 Oct;34(12):994-1003. doi: 10.1177/0333102414523847. Epub 2014 Mar 12. Review.

PMID:
24623124
12.

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.

Goltsov A, Langdon SP, Goltsov G, Harrison DJ, Bown J.

Front Oncol. 2014 Feb 5;4:13. doi: 10.3389/fonc.2014.00013. eCollection 2014.

13.

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D.

Cell Signal. 2013 Jan;25(1):26-32. doi: 10.1016/j.cellsig.2012.09.014. Epub 2012 Sep 18.

PMID:
23000339
14.

Engineering simulations for cancer systems biology.

Bown J, Andrews PS, Deeni Y, Goltsov A, Idowu M, Polack FA, Sampson AT, Shovman M, Stepney S.

Curr Drug Targets. 2012 Nov;13(12):1560-74. Review.

PMID:
22974398
15.

Characterising the tumour morphological response to therapeutic intervention: an ex vivo model.

Savage A, Katz E, Eberst A, Falconer RE, Houston A, Harrison DJ, Bown J.

Dis Model Mech. 2013 Jan;6(1):252-60. doi: 10.1242/dmm.009886. Epub 2012 Aug 10.

16.

Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

Goltsov A, Faratian D, Langdon SP, Mullen P, Harrison DJ, Bown J.

Cell Signal. 2012 Feb;24(2):493-504. doi: 10.1016/j.cellsig.2011.09.030. Epub 2011 Oct 4.

PMID:
21996585
17.

Modelling of healthcare-associated infections: a study on the dynamics of pathogen transmission by using an individual-based approach.

Milazzo L, Bown JL, Eberst A, Phillips G, Crawford JW.

Comput Methods Programs Biomed. 2011 Nov;104(2):260-5. doi: 10.1016/j.cmpb.2011.02.002. Epub 2011 Mar 4.

PMID:
21377229
18.

Modelling fungal colonies and communities: challenges and opportunities.

Falconer RE, Bown JL, McAdam E, Perez-Reche P, Sampson AT, van den Bulcke J, White NA.

IMA Fungus. 2010 Dec;1(2):155-9. Epub 2010 Nov 18.

19.

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.

Goltsov A, Faratian D, Langdon SP, Bown J, Goryanin I, Harrison DJ.

Cell Signal. 2011 Feb;23(2):407-16. doi: 10.1016/j.cellsig.2010.10.011. Epub 2010 Oct 14.

PMID:
20951800
20.

Cancer systems biology.

Faratian D, Bown JL, Smith VA, Langdon SP, Harrison DJ.

Methods Mol Biol. 2010;662:245-63. doi: 10.1007/978-1-60761-800-3_12. Review.

PMID:
20824475
21.

A novel ataxia-telangiectasia mutated autoregulatory feedback mechanism in murine embryonic stem cells.

Clyde RG, Craig AL, de Breed L, Bown JL, Forrester L, Vojtesek B, Smith G, Hupp T, Crawford J.

J R Soc Interface. 2009 Dec 6;6(41):1167-77. doi: 10.1098/rsif.2008.0538. Epub 2009 Mar 4.

22.

Modelling interactions in fungi.

Falconer RE, Bown JL, White NA, Crawford JW.

J R Soc Interface. 2008 Jun 6;5(23):603-15.

23.

Prolactin upregulates its receptors and inhibits lipolysis and leptin release in male rat adipose tissue.

Brandebourg TD, Bown JL, Ben-Jonathan N.

Biochem Biophys Res Commun. 2007 Jun 1;357(2):408-13. Epub 2007 Apr 5.

24.

The role of modelling in identifying drug targets for diseases of the cell cycle.

Clyde RG, Bown JL, Hupp TR, Zhelev N, Crawford JW.

J R Soc Interface. 2006 Oct 22;3(10):617-27. Review.

25.

Biomass recycling and the origin of phenotype in fungal mycelia.

Falconer RE, Bown JL, White NA, Crawford JW.

Proc Biol Sci. 2005 Aug 22;272(1573):1727-34.

26.

The effects of fungal inoculum arrangement (scale and context) on emergent community development in an agar model system.

Sturrock CJ, Ritz K, Samson WB, Bown JL, Staines HJ, Palfreyman JW, Crawford JW, White NA.

FEMS Microbiol Ecol. 2002 Jan 1;39(1):9-16. doi: 10.1111/j.1574-6941.2002.tb00901.x.

27.

Towards a general theory of biodiversity.

Pachepsky E, Crawford JW, Bown JL, Squire G.

Nature. 2001 Apr 19;410(6831):923-6.

PMID:
11309615
28.

Positioning of region 4 of the Escherichia coli RNA polymerase sigma(70) subunit by a transcription activator.

Bown JA, Kolb A, Meares CF, Ishihama A, Minchin SD, Busby SJ.

J Bacteriol. 2000 May;182(10):2982-4.

29.

Reduced hepatic content of dehydroepiandrosterone sulphotransferase in chronic liver diseases.

Elekima OT, Mills CO, Ahmad A, Skinner GR, Ramsden DB, Bown J, Young TW, Elias E.

Liver. 2000 Feb;20(1):45-50.

PMID:
10726960
30.

Positioning of sigma(S), the stationary phase sigma factor, in Escherichia coli RNA polymerase-promoter open complexes.

Colland F, Fujita N, Kotlarz D, Bown JA, Meares CF, Ishihama A, Kolb A.

EMBO J. 1999 Jul 15;18(14):4049-59.

31.

Organization of open complexes at Escherichia coli promoters. Location of promoter DNA sites close to region 2.5 of the sigma70 subunit of RNA polymerase.

Bown JA, Owens JT, Meares CF, Fujita N, Ishihama A, Busby SJ, Minchin SD.

J Biol Chem. 1999 Jan 22;274(4):2263-70.

34.

Diagnostic yield of duodenal biopsy and aspirate in AIDS-associated diarrhea.

Bown JW, Savides TJ, Mathews C, Isenberg J, Behling C, Lyche KD.

Am J Gastroenterol. 1996 Nov;91(11):2289-92.

PMID:
8931404
35.
36.

The effect of income on selenium intake and status in Utah County, Utah.

Christensen MJ, Bown JW, Lei LI.

J Am Coll Nutr. 1988 Apr;7(2):155-67.

PMID:
3361040
37.

A Preschool Program for Children Who Have Communication Problems.

Bown JC, Liston WJ, Ingalls S, Murdock J.

Lang Speech Hear Serv Sch. 1971 Jan 1;2(5):54-57. doi: 10.1044/0161-1461.0205.54. No abstract available.

PMID:
27764266
38.

[Hypertonic elongation of the cervix and Douglas' pouch].

BOWN J.

Scalpel (Brux). 1963 May 25;116:447-52. French. No abstract available.

PMID:
14014657
39.

Diagnostic biologique de la grossesse avec la grenouille Rana esculenta.

BOWN J.

Bull Fed Soc Gynecol Obstet Lang Fr. 1949;1(4):347-9. Undetermined Language. No abstract available.

PMID:
15396028

Supplemental Content

Support Center